A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P4502C8




TekijätTornio A, Pasanen MK, Laitila J, Neuvonen P, Backman JT

KustantajaWILEY

Julkaisuvuosi2005

JournalBasic and Clinical Pharmacology and Toxicology

Tietokannassa oleva lehden nimiBASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Lehden akronyymiBASIC CLIN PHARMACOL

Vuosikerta97

Numero2

Aloitussivu104

Lopetussivu108

Sivujen määrä5

ISSN1742-7835

DOIhttps://doi.org/10.1111/j.1742-7843.2005.pto_134.x


Tiivistelmä
Statins are involved in different types of drug interactions. Our objective was to study the effect of statins on cytochrome P450 (CYP) 2C8-mediated paclitaxel 6 alpha-hydroxylation by incubating paclitaxel and statins (0-100 mu M) with pooled human liver microsomes. Simivastatin, lovastatin, atorvastatin and fluvastatin were the most potent inhibitors of CYP2C8 activity with K-i (IC50) values of 7.1 (9.6) mu M, 8.4 (15) mu M, 16 (38) mu M and 19 (37) mu M, respectively. Cerivastatin, simvastatin acid and lovastatin acid were less potent inhibitors with Ki (IC50) values ranging from 32 to 55 (30-67) mu M. Rosuvastatin and pravastatin showed no appreciable effect on CYP2C8 activity even at 100 mu M. In conclusion, all the statins tested, except rosuvastatin and pravastatin, had a significant inhibitory effect on the activity of CYP2C8 in vitro. Because many of the statins accumulate in the liver and because also their metabolites may inhibit CYP2C8 activity, in vivo studies are needed to investigate a possible interaction of simvastatin, lovastatin, atorvastatin and fluvastatin with CYP2C8 substrate drugs.



Last updated on 2024-26-11 at 23:15